e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by VERAXA Biotech GmbH
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
July 10, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
July 06, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
July 02, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
June 24, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
June 18, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
June 10, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
May 28, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
March 02, 2026
From
VERAXA Biotech GmbH
Via
GlobeNewswire
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
September 30, 2025
From
VERAXA Biotech GmbH
Via
GlobeNewswire
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
May 05, 2025
From
VERAXA Biotech GmbH
Via
GlobeNewswire
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
April 23, 2025
From
VERAXA Biotech GmbH
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.